Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

121 results about "Desmethyl" patented technology

Desmethyl is a term used in organic chemistry to refer to a methyl group that has been removed. Examples include desmethyltramadol and desmethylsertraline.

Enzymes for synthesis of glabridin

The invention relates to the field of biological engineering and technology, in particular to an enzyme for synthesizing glabridin, a biological synthesis method of glabridin and an engineering-modified biological host. The invention discloses a series of glabridin synthesizing enzymes (4 '-O-methyltransferase, isoflavone 2'-hydrogenase, isoflavone reductase, Vissisoketoreductase, isoprenyltransferase, pterocarpin reductase, oxidative cyclase and demethylase) from glycyrrhiza glabra for the first time, and the glabridin synthesizing enzymes have corresponding activities in various biological hosts. The heterologous biosynthesis of the glabridin is realized for the first time, and the yield of the glabridin can reach 60% or above.
Owner:TSINGHUA UNIVERSITY

Reservoir system comprising cariprazine or salt thereof

PendingCN119136804AOrganic active ingredientsPowder deliveryCariprazineProlonged release
The present invention provides a long-acting parenteral pharmaceutical composition in a depot form comprising a therapeutically effective amount of cariprazine or a pharmaceutically acceptable salt thereof, suitable for administration at a medically acceptable location in a subject in need thereof. The depot composition is preferably in the form of an orthotopic implant suitable for subcutaneous or intramuscular administration and provides prolonged release of the cariprazine active ingredient and / or metabolites thereof demethylcariprazine (DDCAR) and didemethylcariprazine (DDCAR) after a single administration for a period of at least four weeks. The present invention also provides methods of treating schizophrenia, major depression, and bipolar disorder using the depot compositions.
Owner:MAPI PHARMA LTD

Combination of trifluoromethyl-containing compound and chemotherapeutic drug for treatment of hematologic tumors

The invention belongs to the field of medicine, relates to application of a combination containing a trifluoromethyl compound and a chemotherapeutic drug including a demethylated drug to treatment of hematologic tumors, and particularly relates to application of a combination of a salt shown as a formula I-1 or pharmaceutically acceptable salt thereof and a chemotherapeutic drug to treatment of hematologic tumors. # imgabs0 #
Owner:CHIA TAI TIANQING PHARMA GRP CO LTD

Adriamycin-tetravalent platinum drug-norcantharidin three-drug combined nano-drug as well as preparation method and application thereof

The invention discloses an adriamycin-tetravalent platinum drug-norcantharidin three-drug combined nano-drug as well as a preparation method and application thereof, and belongs to the technical field of medical materials. A tetravalent platinum drug modified by demethylated cantharidin and adriamycin are used as raw materials, a novel nano-drug is constructed through Cu < 2 + > coordination, and then the nano-drug combining adriamycin, the tetravalent platinum drug and demethylated cantharidin is prepared by polymerizing polydopamine with a mild photo-thermal effect. The polymer has the capacity of controllably releasing drugs under acidity and reduction, can realize photo-thermal conversion under laser irradiation to generate a mild photo-thermal effect, has a better tumor cell killing effect, has the capacity of consuming glutathione and generating hydroxyl radicals, can enter cancer cells in an endocytosis mode and release DOX, and can be used for killing tumor cells. And a new thought is provided for multi-drug combination and chemotherapy-chemokinetics therapy-photothermal therapy multi-mode combined therapy.
Owner:QILU UNIVERSITY OF TECHNOLOGY (SHANDONG ACADEMY OF SCIENCES)

Demethylase ODM gene for synthesizing benzylisoquinoline alkaloid and application of demethylase ODM gene

The invention discloses a demethylase ODM gene for synthesizing benzylisoquinoline alkaloids and application thereof, the demethylase ODM gene is an ODM1 gene or an ODM2 gene, the nucleotide sequence of the CDS region of the ODM1 gene is shown as SEQ ID NO: 1, and the nucleotide sequence of the CDS region of the ODM2 gene is shown as SEQ ID NO: 2. Aiming at the current situation that the research basis of a key gene for synthesizing corydalmine in rhizoma corydalis is weak, the ODM1 gene for catalyzing tetrahydropalmatine demethylation to specifically generate corydalmine and tetrahydrojatrorrhizine and the ODM2 gene for specifically generating tetrahydrojatrorrhizine are cloned from rhizoma corydalis for the first time. An important theoretical basis is provided for producing the corydalmine by utilizing a synthetic biological method in the future, and the corydalmine mutant has a wide application prospect and a great economic value.
Owner:CHINA PHARM UNIV

Method for efficiently purifying nitric acid

The invention relates to a method for efficiently purifying nitric acid and belongs to the technical field of nitric acid preparation. The method comprises the following steps: diluting 98% industrial-grade nitric acid into 68% nitric acid by adding deionized water; the method comprises the following steps: adding a metal ion stabilizer and a stabilizing synergist into 68% nitric acid, feeding into a heat exchanger, and heating by steam to gasify; purifying the gasified nitric acid steam through a rectifying tower, feeding the purified nitric acid steam into a condenser, continuously introducing nitrogen into the condenser, and dehydrating and decoloring; after the decoloration is qualified, obtaining high-purity nitric acid; the disqualified decolorized product is returned to the heat exchanger for re-purification; the stabilizing synergist is prepared by adopting 3-mercaptoquinoline, 4, 4 '-divinyl-2, 2'-dipyridyl, tetra (4-boric acid phenyl) ethylene, N-methyl pyrrolidone and a photoinitiator, stirring at normal temperature, irradiating with an ultraviolet lamp to react, and performing reduced pressure distillation to remove the N-methyl pyrrolidone; the stable synergist prepared by the invention has higher metal impurity adsorption capacity and chelating effect, and can efficiently purify nitric acid.
Owner:ZHEJIANG KAISN FLUOROCHEM

Preparation method and control of abelsilil impurity A

The invention relates to the technical field of chemical synthesis, and discloses a preparation method and control of an abelsiril impurity A, namely 6-(4-chloro-5-fluoropyrimidine-2-yl)-4-fluoro-1-isopropyl-2-methyl-1H-benzimidazole. The preparation method comprises the following steps: S1, carrying out aromatic nucleus nucleophilic substitution reaction on a compound I and a nucleophilic reagent in an organic reagent, washing an organic phase, drying, filtering, and drying to obtain a compound II; concentrating under reduced pressure to obtain a compound II; s2, mixing the compound II, the compound III, a palladium catalyst, alkali and an organic solvent, performing heating reflux under the protection of nitrogen, performing Suzuki coupling reaction, performing vacuum concentration, and washing a filter cake with tetrahydrofuran to obtain a compound IV; s3, carrying out demethylation reaction on the compound IV to obtain a compound V; s4, the compound V reacts with a chlorination reagent, reduced pressure distillation is conducted, separation and purification are conducted, and the abelsilib impurity A is obtained. The design route provided by the invention is reasonable, the reaction site selectivity is good, and the impurity A with relatively high purity can be obtained.
Owner:JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD

Development of lysine-specific demethylase 1 (LSD1) inhibitors as Anti-cancer reagents

The present disclosure is concerned with substituted cyclopropyl carbamate and cyclopropyl sulfonamide compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds in the treatment of various cancers such as, for example, cancers comprising cells that express at least one Sox 2 stem cell marker. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:BOARD OF RGT NEVADA SYST OF HIGHER EDUCATION ON BEHALF OF THE UNIV OF NEVADA RENO

A process for the synthesis of oestrone from androsta-1,4-diene-3,17-dione

The present application relates to a kind of from androsta 1, 4-diene-3, 17-dione starting synthesis of estren and the method of a kind of compound thereof.Especially, the present application provides a kind of preparation method of estren shown in formula I, comprising the following steps: in inert solvent, androsta-1, 4-diene-3, 17-dione (II) with reagent R4VX carries out demethylation aromatization reaction step directly to obtain estren (I);Wherein, the definition of reaction substrate, reagent and reaction condition is as claimed in claim or specification.The method is simple in operation, and good in selectivity, and product purity is high, suitable for industrial production.
Owner:SHANGHAI INST OF ORGANIC CHEM CHINESE ACAD OF SCI

N-desmethyl ruboxistaurin as a RSK inhibitor for therapeutic use

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate RSK signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit RSK. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects with cancer, including breast cancer, ovarian cancer, prostate cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, osteosarcoma, myeloproliferative neoplasms, leukemia, and bladder cancer. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, inhibits RSK and shows a safety profile that supports its long-term use.
Owner:4M THERAPEUTICS INC

Compositions and methods for augmenting VEGF therapy for ischemic tissue revascularization

Provided herein are compositions including a CRISPR / dCas9-based demethylation cocktail targeting a methylated endothelial PLCγ2 promoter and methods of treating wounds using the same.
Owner:UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION

An oxygen-tolerant Blautiae strain and its application in aerobic synthesis of 3′-demethylarcigenin

The present invention relates to the field of microbial technology, and specifically discloses an oxygen-resistant Blautia sp. and its application in the aerobic synthesis of 3'-demethyl arctiin. The oxygen-resistant Blautia sp. (Blautia sp.) Aeroto-AUH-df6 has a deposit number of CGMCC NO.30297. The oxygen-resistant Blautia sp. Aeroto-AUH-df6 provided by the present invention can efficiently transform arctiin under the condition of air oxygen, and the transformation performance is stable, which solves the problem that 3'-demethyl arctiin cannot be biosynthesized on a large scale under the condition of air oxygen, and the problem that 3'-demethyl arctiin resources are scarce, and 3'-demethyl arctiin is the only product of the transformation of the substrate arctiin by the strain Aeroto-AUH-df6, which greatly simplifies the subsequent separation and purification steps, and is of great significance for studying the pharmacological activity of 3'-demethyl arctiin and the development of new drugs.
Owner:HEBEI AGRICULTURAL UNIV.

Sterol compound, preparation method and medicine for treating pulmonary fibrosis

The invention relates to a sterol compound, a preparation method and a medicine for treating pulmonary fibrosis, and belongs to the technical field of medicines. The demethylated cryptosterol separated from the fungus coniothyrium minitans has good anti-pulmonary fibrosis activity, and can be used as a lead compound for developing drugs for treating idiopathic pulmonary fibrosis. The invention provides an alternative compound for developing a new medicine for treating idiopathic pulmonary fibrosis, and has very important significance for development and utilization of natural product resources.
Owner:HUBEI THREE GORGES POLYTECHNIC

Metabolite marker for colorectal cancer diagnosis and application thereof

The invention relates to a metabolite marker for early diagnosis of colorectal cancer as well as application and a device of the metabolite marker. The marker comprises sulfate, ubiquinone-1, a deoxycholic acid glycine conjugate, demethylchlorophyllin, 3-(3, 5-diiodine-4-hydroxyphenyl) lactate, vitamin K1, O-decanoyl-L-carnitine, sedoheptulose 1, 7-diphosphoric acid, cholesterol-docosahexaenoic acid ester and acyl AMP (adenosine monophosphate). The marker combination has excellent performance in colorectal cancer detection, AUROC can reach 0.97, and noninvasive screening and early diagnosis of colorectal cancer can be accurately, quickly and simply realized.
Owner:MACAU UNIV OF SCI & TECH

Colchicine derivatives for resisting multiple myeloma as well as preparation method and application of colchicine derivatives

The invention discloses a series of colchicine deuterated derivatives for resisting multiple myeloma, which can effectively inhibit proliferation of multiple myeloma cells by improving the metabolic effect of colchicine in the multiple myeloma cells and overcome the defect of large toxic and side effects of metabolism of original drugs. According to the series of colchicine deuterated derivatives capable of resisting multiple myeloma, colchicine is used as a raw material, two reactions of demethylation and deuterated methyl are sequentially performed to obtain a target compound, the reaction steps are few, the reaction conditions are mild, the operability is high, and the efficiency is high.
Owner:NANJING UNIV OF TRADITIONAL CHINESE MEDICINE

Method for detecting multiple antitumor drugs and metabolites in human plasma through liquid chromatography-tandem mass spectrometry and application

The invention relates to the technical field of drug monitoring, and mainly relates to a method for detecting multiple antitumor drugs and metabolites in human plasma through liquid chromatography-tandem mass spectrometry and application of the method. The medicine to be detected is prepared from cevaltinib, loratinib, vomitinib, amitinib, sovantinib, anlotinib, glutamitinib, emtricitinib, N-demethylated vomitinib and N-demethylated emtricitinib; s2, preparing a calibration product and a quality control product, and preparing a working curve concentration table; s3, carrying out pretreatment on the calibration product and the quality control product obtained in the step S2; s4, carrying out liquid chromatography-tandem mass spectrometry detection on the pretreated liquid; and S5, performing methodological verification on the detection method. The detection method has the advantages of high sensitivity, good detection result accuracy, simple and rapid detection process, short analysis time and the like, and is suitable for detection of large-flux samples.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL +1

Imidazo [1, 2-alpha] pyridine group-containing bidentate cobalt complex as well as preparation method and application thereof

The invention provides a bidentate cobalt complex containing an imidazo [1, 2-alpha] pyridine group as well as a preparation method and application of the bidentate cobalt complex, and belongs to the technical field of organic chemical synthesis. The structural formula of the bidentate cobalt complex is shown in the specification, and the preparation method comprises the following steps: carrying out bromination reaction and cyclization reaction on 2-methoxy-6-acetylpyridine to obtain a bidentate ligand with methoxy and imidazo [1, 2-alpha] pyridyl, and carrying out demethylation reaction on the ligand to obtain another bidentate cobalt complex with hydroxyl and imidazo [1, 2-alpha] pyridyl. The imidazo [1, 2-alpha] pyridyl-containing bidentate cobalt complexes are prepared from imidazo [1, 2-alpha] pyridyl-containing bidentate ligands, and the two ligands react with anhydrous cobalt chloride respectively to obtain various imidazo [1, 2-alpha] pyridyl-containing bidentate cobalt complexes. The electron effect of the complex is adjusted by changing substituent groups on imidazo [1, 2-a] pyridine groups, then the activity of the complex in catalytic reaction is adjusted, and the complex can be further applied to hydrosilylation reaction of styrene and has very important application prospects.
Owner:ZHENGZHOU UNIV

Medical application of O-demethylangorapin

The invention provides an application of O-demethylangorapin in preparation of a medicine for relieving renal toxicity and myotoxicity of cis-platinum and cachexia manifestation caused by the renal toxicity and the myotoxicity of the cis-platinum. The active ingredient of the medicine is one or more of O-demethylated angorapin, a hydrate of the O-demethylated angorapin, a pharmaceutically acceptable salt of the O-demethylated angorapin, a tautomer of the O-demethylated angorapin, a stereoisomer of the O-demethylated angorapin and a precursor compound of the O-demethylated angorapin. The O-demethylangiecarpin has the potential to be developed into a drug for relieving the toxicity of cis-platinum.
Owner:SHANGHAI UNIV OF T C M

A method for preparing a 6- or 10-oxidized modified steroid drug

ActiveCN117285583BAir atmospherePtru catalyst
The application provides a preparation method of a 6-position or 10-position oxidatively modified steroid drug, and the method comprises the following steps: S1: irradiating a solution of 19-methyl steroid drug Ia or 19-demethyl steroid drug Ib and a catalyst with a light source under an oxygen or air atmosphere, and removing the solvent after the irradiation is completed; S2: treating the reaction product after the solvent removal in S1 with a reducing agent, so that 6-position oxidatively modified steroid drug IIa and IIIa or 10-position oxidatively modified steroid drug IIb is obtained. In the preparation method, no reagent with high danger and environmental pollution, such as metal, strong base or peroxide, is used, the yield is high, the method is green, environmentally friendly, simple and easy to implement, and the production applicability is strong.
Owner:SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES

Preparation method of 7-demethylated amamicycline

The invention belongs to the field of medicine synthesis, and particularly discloses a preparation method of 7-demethylated amazonicycline. The preparation method comprises the following steps: by taking 7-aminosancycline as an initial raw material, adding N-benzyl and N-methyl, then carrying out substitution reaction by using N-hydroxymethyl phthalimide, then removing phthaloyl by using methylamine, carrying out amination reduction reaction by using sodium borohydride and pivalaldehyde, and finally, carrying out hydrogenation by using pd / C to remove benzyl, thereby obtaining the 7-methyl oxalicycline. According to the route, the target product can be prepared with the total yield of 55%. According to the method, the impurity reference substance of the high-purity 7-methyl omalonin can be prepared, the accuracy of qualitative and quantitative analysis of the impurity is improved, the control on the impurity is enhanced, and the quality of an omalonin finished product is further improved.
Owner:CHONGQING CHANGJIE MEDICINE CHEM +1

Compounds inhibiting histone lysine demethylase and uses thereof

The invention relates to a compound, which has good H3K27me3 demethylation inhibition activity at a cellular level, can effectively inhibit KDM6A / B activity, and can effectively treat inflammation and tumor diseases. The compound is shown in the formula.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +1

Polymorphs of N-Desmethyl Ruboxistaurin and Salts Thereof

Novel compositions of N-desmethyl ruboxistaurin L-lactate salt and L-lactate salt polymorphs. The use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to modulate GSK-3 signaling is disclosed, as is the use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to inhibit protein kinase C. Methods are also disclosed of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in the treatment of subjects having a neurological disease and / or psychiatric disorder, including Alzheimer's disease, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation, as well as methods of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. In addition, compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs administered in combination with lithium or other treatments for bipolar disorder are also disclosed.
Owner:4M THERAPEUTICS INC

Method of preparing ionic fluids

A method of preparing MEP including the steps of: (a) adding N-methylpyrrolidine to an excess amount of ethyl bromide located in a reactor, wherein the N-methylpyrrolidine will react with the ethyl bromide forming MEP, wherein the reaction will have a reaction temperature that can varies over time; (b) stopping addition of N-methylpyrrolidine when the excess of ethyl bromide to the N-methylpyrrolidine falls within a range of 3:1 to 1.5:1; (c) adding water to the reactor creating a two phase system to develop which includes: (i) a top layer containing aqueous MEP and (ii) a bottom layer containing ethyl bromide; (d) separating the top layer from the bottom layer yielding a first aqueous solution of MEP and a second solution of ethyl bromide; and (e) removing N-methylpyrrolidine and ethyl bromide from the first aqueous solution of MEP.
Owner:TETRA TECHNOLOGIES INC

A method for preparing minocycline hydrochloride and its intermediates

This invention discloses a compound of formula I and a method for preparing minocycline hydrochloride. The method for preparing compound I involves dissolving 6-demethyltetracycline in acidic water, adding a chlorination reagent for chlorination, then adding p-aminobenzenesulfonic acid diazonium hydrochloride and alkaline solution for coupling reaction, followed by post-treatment. The method for preparing minocycline hydrochloride uses 6-demethyltetracycline as a starting material, proceeding through the intermediate of compound I, and removing the C7 chlorine, p-aminobenzenesulfonic acid group, and C6 hydroxyl group via catalytic hydrogenation, followed by reductive amination and post-treatment. This invention achieves low-pressure palladium-carbon catalytic removal of the C6 hydroxyl group by introducing an electron-donating amino group at the C7 position, eliminating the need for expensive rhodium-carbon catalysts. The reaction conditions are mild, column chromatography purification is unnecessary, the overall yield is ≥85%, and the product purity is ≥96%, making it suitable for industrial production.
Owner:CHONGQING SHENGHUAXI PHARMA CO LTD +1

N-desmethyl ruboxistaurin as a kinase inhibitor

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate GSK3|3 signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit protein kinase C. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects having a neurological disease and / or psychiatric disorder, including Alzheimer's disease, frontotemporal dementia, behavioral complications of dementia, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation. Some aspects of this invention provide methods of using N-desmethyl ruboxistaurin in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin as an alternative to ruboxistaurin, with a better pharmacokinetic profile, lower potential for prolongation of the electrocardiogram QT interval, and / or a lower potential for adverse drug interactions. In some embodiments, N-desmethyl ruboxistaurin is administered in combination with lithium or other treatments for bipolar disorder.
Owner:4M THERAPEUTICS INC

Methods for producing lysine-specific demethylase 1 (LSD1) inhibitors

To provide a production method of lysine-specific demethylase (LSD1) inhibitors that is easier to implement and has higher yields.SOLUTION: A method for producing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof comprises the step of converting a compound C to a compound D in a solvent under the action of an oxidizing agent.SELECTED DRAWING: None
Owner:JIANGSU LIANHUAN PHARMA +1

Ultrasonic sensitization nanometer material based on MOFs and preparation method and application of ultrasonic sensitization nanometer material

The invention discloses an ultrasonic sensitized nano material based on MOFs (Metal-Organic Frameworks) as well as a preparation method and application thereof, and belongs to the technical field of biological materials. Comprising drug-loaded MOFs; the MOFs is selected from the group consisting of UiO-66-NH2; the UiO-66-NH2 is a particle formed by connecting an amino functional group to UiO-66; an m6A-mRNA (Messenger Ribonucleic Acid) demethylase inhibitor compound is loaded in the medicine carrying MOFs; the m6A-mRNA demethylase inhibitor compound is formed by coordination of a Rhein molecule and a bivalent copper ion; the outer surface of the drug-loaded MOFs is combined with an anti-CD19 antibody; and the outer surface of the drug-loaded MOFs is also modified with mPEG-PO3 (mPEG (Polyethylene Glycol)-PO3). As a replacement therapy of BCL, the MOFs-based ultrasonic sensitized nanomaterial can specifically gather in BCL tissues to play a therapeutic role after being functionalized by mPEG-PO3 and an anti-CD19 antibody.
Owner:JILIN UNIVERSITY

Method for detecting content of N-nitroso-demethylated olopatadine in olopatadine hydrochloride bulk drug

The invention relates to the technical field of medicine analysis, in particular to a method for detecting the content of N-nitroso-demethylated olopatadine in an olopatadine hydrochloride raw material medicine. The analysis method comprises the following steps: preparing a blank solution, a system applicability solution and an olopatadine hydrochloride bulk drug test solution; sequentially injecting the blank solution, the system applicability solution and the olopatadine hydrochloride raw material medicine test solution, injecting into a high performance liquid chromatography-tandem mass spectrometer, and detecting the content of N-nitroso-demethylated olopatadine according to an external standard method; the invention discloses a method for detecting the content of N-nitroso-demethylated olopatadine in an olopatadine hydrochloride bulk drug, which has the advantages of high sensitivity, simplicity, rapidness, strong specificity, good accuracy, high precision, good stability and good linear relationship, and can be used for detecting the content of N-nitroso-demethylated olopatadine in the olopatadine hydrochloride bulk drug.
Owner:JIANGSU YABANG AIPUSEN PHARMA

New compounds for promoting hair growth and compositions containing them

The present invention relates to novel compounds which can be used as the main component of a composition for stimulating hair growth, and also to their use in stimulating hair growth, wherein the novel compounds are 9-deoxy-31-O-demethyl-proline-FK506, 9-deoxy-36,37-dihydro-FK506, 31-O-demethyl-36,37-dihydro-FK506, 9-deoxy-31-O-demethyl-36,37-dihydro-FK506, 9-deoxy-FK520, 31-O-demethyl-FK520, 9-deoxy-31-O-demethyl-FK520, 9-deoxy-FK523 and 9-deoxy-31-O-demethyl-FK523.
Owner:MORGAN BIOTECHNOLOGY CO LTD

Photoenzyme catalytic reaction for producing methane through oxygen demethylation of aryl methyl ether and application of photoenzyme catalytic reaction

The invention relates to a photo-enzyme catalytic reaction for producing methane through oxygen demethylation of aryl methyl ether and application of the photo-enzyme catalytic reaction. According to the method, demethylase MTase I and cobalamine binding protein CP which are purified by a nickel column are utilized, the demethylase MTase I, the cobalamine binding protein CP and 5-denitrified riboflavin react with different aryl methyl ether substrates respectively in a buffer solution with the pH value of 6.5 under the conditions of purple light irradiation and anaerobic conditions, O-demethylation of aryl methyl ether is catalyzed, and the 5-denitrified riboflavin is obtained. Demethylation products of methane and phenols are generated; according to the method disclosed by the invention, demethylation methane production reaction is completed, and meanwhile, the reaction efficiency and the substrate spectrum of oxygen demethylation of aryl methyl ether are improved. In-vitro catalysis of the demethylation methane production reaction of flavone aryl ether and natural biomass lignin alkaline hydrolysate is realized for the first time, and compared with the current demethylation reaction, the method has the advantages of mild reaction conditions, environmental protection and the like, and meanwhile, the removed methyl is converted into methane, so that the method is suitable for industrial production. The addition of additional methyl acceptors and the generation of byproducts are effectively avoided, and the atom economy is improved.
Owner:TIANJIN UNIV